期刊文献+

冠心病介入治疗致造影剂肾病六例临床分析 被引量:4

原文传递
导出
摘要 目的探讨冠心病介入治疗导致造影剂肾病(CIN)的诱发因素,总结出因素之后有针对性的进行预防措施的制定。方法回顾性分析100例介入治疗冠心病的临床资料,总结分析发生CIN的影响因素。结果100例患者,有6例发生了介入治疗致GIN(6.0%),CIN患者合并高血压病、原有肾功能不全病史以及糖尿病的比例明显高于非CIN患者(均P〈0.05),CIN患者左室射血分数(LVEF)水平、24h内水化量明显低于非CIN患者(均P〈0.05)。结论在对患者进行冠心病介入之前,应对临床资料仔细检查,若存在有导致造影剂肾病的高危因素就应该要注意。同时要用水化疗法预防,能够在最大程度改善以及纠正各高危因素,有效的避免CIN情况的发生。
出处 《中国基层医药》 CAS 2013年第18期2840-2841,共2页 Chinese Journal of Primary Medicine and Pharmacy
  • 相关文献

参考文献13

二级参考文献129

  • 1孙蔚明,杜晔.非离子型造影剂致肾损害的临床分析[J].中国医学影像学杂志,2005,13(4):284-287. 被引量:24
  • 2吉俊,丁小强,许迅辉,邹建洲,何建强,林贻梅,柏瑾,钱菊英.低渗非离子造影剂对冠状动脉介入诊疗术患者肾功能影响的前瞻性研究[J].中华肾脏病杂志,2006,22(7):388-392. 被引量:46
  • 3汪斌,刘志忠,张丰富.冠状动脉介入诊治中高敏C反应蛋白与造影剂肾病的相关性分析[J].中国医药,2007,2(8):457-459. 被引量:35
  • 4Sousa CS, Pedro MM, Pinto FJ. Contrast-induced nephropathy following percutaneous coronary intervention: case report[J]. Rev PortCardiol, 2009, 28 (3) : 309-321.
  • 5Murghy SW, Barrett BJ, Pafrey PS.Contrast nephropathy[J]. J Am Soc Nephrol, 2000, 11 (2) : 177-182.
  • 6Gruberg L, Mehran R, Dangas G, et al.Acute renal failure requiring dialysis after percutaneous coronary interventions[J]. Cathet Cardiovasc Interven, 2001, 52: 409--416.
  • 7Richard J Solomon, Madhu K Natarajan, Serge Doucet, et al. Cardiac angiography in renally impaired patients (CARE) study,A randomized double-blind trial of contrast- induced nphropathy in ptients with chronic kidney disease[J].Circulation, 2007, 115: 3189-3196.
  • 8Pdhal CS, Texter SC, Gill DE, et al.Incidence and prognostic importance of acute renal failure after perentaneour coronary imervention[J].Circulation, 2002, 105(19): 2259-2262.
  • 9Richard JS, Madhu KN, Serge D, et al.Sodium bicarbonate vs sodium chloride for the prevention of contrast medium- induced nephropathy in patients undergoing coronary angiography: A randomized trial[J].JAMA, 2008, 300:1038-1046.
  • 10[20]Morcos SK,Thomsen HS,Webb JA,et al.Dialysis and contrast media[J].Eur Radiol,2002,12 (12):3026-3030.

共引文献126

同被引文献25

  • 1Mehran R, Nikolsky E. Contrast - induced nephropathy: definition,epidemiology,and patients at risk [ J ]. Kidney Int Suppl,2006,(100);S11-S15.
  • 2Kitajima K, Maeda T, Watanabe S,et al. Recent issues in contrast -induced nephropathy[ J]. Int J Urol,2011,18( 10) :686-690.
  • 3Rihal CS, Textor SC, Grill DE, et al. Incidence and prognosticimportance of acute renal failure after percutaneous coronaryintervention[ J]. Circulation,2002 ,105 ( 19 ) :2259-2264.
  • 4Bashaw SM, Culleton BF. Contrast-induced nephropathy: Epidemiologyand prevention[J]. Minerva Cardioangiol, 2006,54(1) : 109-129.
  • 5Nikolsky E,Mehran R, Lasic Z,et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions [J]. Kid-ney Int, 2005,67(2) :706-713.
  • 6Bartholomew BA, Haijai KJ, Dukkipati S, et al. Impact of nephropa-thy after percutaneous coronary intervention and a method for riskstratification[J]. Am J Cardiol,2004,93( 12) :1515-1519.
  • 7McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy [J]. Am J Cardiol ,2006 , 98(6A) :27K-36K.
  • 8Briguori C, Airoldi F,Andrea D, et al. Renal insufficiency followingcontrast media administration trial( REMEDIAL) :a randomized com-parison of 3 preventive strategies[ J]. Circulation, 2007,115 (10):1211-1217.
  • 9Ozhan H,Erden I,Ordu S,et al. Efficacy of short-term high-dose ator-vastatin for prevention of contrast-induced nephropathy in patients un-dergoing coronary angiography [ J ]. Angiology, 2010,61 (7):711-714.
  • 10Melfi R,Nusca A,Patti G,et al. Statins and their role in prepercutane-ous coronary intervention [ J ]. Curr Cardiol Rep,2010,12 ( 4 ):295-301.

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部